著者

Zhen-Guang Li Zhan-Cai Yu Yong-Peng Yu Dao-Zhen Wang Wei-Ping Ju Qi-Zhuan Wu

出版者

Japan Brain Science society

雑誌

脳科学誌 (ISSN:13415301)

巻号頁・発行日

vol.37, pp.35-46, 2011 (Released:2017-06-01)

参考文献数

32

---

Lysophosphatidic acid (LPA) is released from activated platelets. Statins are the commonly used anti-atherosclerotic drug. The purpose of this study is to observe whether atorvastatin could decrease the plasma LPA levels in ischemic stroke patients. A total of 386 subjects, including the 247 ischemic stroke cases and 139 healthy controls, were enrolled in this study. The 247 ischemic stroke cases were divided into Group A (n=109) and Group B (n=138) who had and had not received atorvastatin treatment before a stroke respectively. The plasma LPA levels of all the subjects were measured using chromatography. There was significant diffidence in the LPA levels between cases and controls (3.22±1.51μmol/L vs. 1.83±1.07μmol/L, p<0.01). The plasma LPA level in Group A was lower than that of Group B (2.66±1.23umol/L vs. 3.83±1.14umol/L, p<0.01). Atorvastatin (20mg/d) significantly reduced LPA levels in ischemic stroke patients (n=138) compared with that before atorvastatin administration (1.96±0.87μmol/L vs. 3.83±1.14μmol/L, p<0.01). However, the LPA levels re-elevated after atorvastatin withdrawl for one month. Atorvastatin could decrease the plasma LPA levels in patients with ischemic stroke, which providing a better understanding of how statins protect against ischemic stroke. It is plausible to speculate that statins might have an effect of anti platelet activation.